Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (388)	11/21/1999 12:01:00 PM
From: Bob L	Respond to of 666

Right, pretreatment is as much or more of a factor than the natural variation in NHL cellular classification among patients. "Two hem-oncs of my acquaintance have previously told me they'd have a CHOP-Rit preference over Bex. " Had they seen the fludarabine-bexxar data when they said that? Fludarabine is already well established as a first line treatment. If adding bexxar does tend to convert PR to CR, it will be an attractive option. It all depends so much the individual patient's condition. There is plenty of room for all of these treatment options.